Skip to main content

Table 2 Univariate and multivariate analyses of factors for the OS

From: Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy

  

Median OS

Univariate analysis

Multivariate analysis

n

(mean ± SD)

HR

95%CI

p-value

HR

95%CI

p-value

Age

<65 years

32

2122 (2221.6 ± 1725.5)

1

0.50-4.73

0.453

   

≥65 years

42

718 (1071.4 ± 1003.6)

1.54

     

Gender

Female

16

767 (1891.9 ± 1536.9)

1

0.50-12.02

0.272

   

Male

58

980 (1479.6 ± 13743.5)

2.44

     

ECOG-PS

0

68

1286 (1673.7 ± 1413.1)

1

0.7021.22

0.121

   

≥1

6

302 (379.3 ± 319.4)

3.86

     

NLR

<2.38

51

1250.5 (1576.6 ± 1375.0)

1

1.54-15.23

0.007

1

1.16-18.34

0.030

≥2.38

23

797.5 (1551.3 ± 1487.5)

4.84

  

4.62

  

CPR

<0.08

23

1427 (1461.3 ± 1091.4)

1

1.24-81.27

0.030

1

1.06-110.29

0.045

≥0.08

51

772 (1617.2 ± 1533.2)

10.06

  

10.8

  

LDH

<158

20

1286 (1464.7 ± 1205.3)

1

0.36-4.47

0.712

   

≥158

54

808 (1607.3 ± 1565.7)

1.27

     

Neoadjuvant Chemotherapy

No

64

1244 (1535.9 ± 1339.8)

1

0.15-4.10

0.772

   

Yes

10

331 (1779.3 ± 2228.4)

0.78

     

Clinical T stage

≤2

38

980 (1828.6 ± 1722.9)

1

0.39-3.47

0.781

   

≥3

36

818 (1294.5 ± 1114.1)

1.67

     

Clinical Lymph Node Metastasis

No

70

818 (1566.6 ± 1492.3)

1

0.11-11.57

0.921

   

Yes

4

1671 (1607.3 ± 615.3)

1.13

     

Sugical Margin

Negative

68

11271.5 (1616.1 ± 1431.6)

1

0.85-7.74

0.095

   

Positive

6

707 (1287.8 ± 2064.0)

2.56

     

Adjuvant chemotherapy

No

49

722 (1189.7 ± 1200.8)

1

0.48-4.52

0.493

   

Yes

25

2154 (2311.7 ± 1624.5)

1.48

     

Pathological T stage

≤2

53

1112 (1586.9 ± 1466.4)

1

0.32-3.52

0.914

   

≥3

21

982 (1437.4 ± 1603.1)

1.07

     

Pathological Lymph Node Metastasis

No

64

1244 (1609.8 ± 1466.4)

1

1.17-19.17

0.030

1

1.85-82.47

0.009

Yes

10

718 (1305.9 ± 1523.6)

4.73

  

12.35

  
  1. OS: overall survival, ECOG-PS: Eastern Cooperative Oncology Group performance status, NLR: neutrophil-to-lymphocyte ration
  2. CPR: C-reactive protein, LHD: lactate dehydrogenase